Indalo Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Indalo Therapeutics, Inc. - overview
Location
St. Louis, MO, US
Primary Industry
Pharmaceuticals
About
Based in Missouri, US, and founded in 2016, Indalo Therapeutics, Inc operates as a biopharmaceutical company that develops integrin antagonists for patients suffering from serious fibrotic diseases such as nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF). The firm was founded as a merger between Cascadian Therapeutics, Inc. , and Antegrin Therapeutics LLC. In January 2019, Indalo Therapeutics, Inc.
raised USD 26 million in series A funding co-led by Atlas Venture and Atlas Venture, Missouri Technology Corporation, and BioGenerator. The company's IDL-2965 is an oral, selective antagonist of RGD-binding integrins avb1, avb3, and avb6 that inhibits numerous stages of pathologic fibrosis, including the local stimulation of TGF-b by both epithelial cells and fibroblasts.
Current Investors
Atlas Venture, F-Prime Capital, BioGenerator
Primary Industry
Pharmaceuticals
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.indalotherapeutics.com
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.